Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2019

01-01-2019 | Images in Hematology

Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia

Authors: Tatsuya Konishi, Noriko Doki, Yasunobu Takaki, Aiko Igarashi, Kazuteru Ohashi

Published in: International Journal of Hematology | Issue 1/2019

Login to get access

Excerpt

Accumulated clinical experience has now provided clear and convincing evidence that erythropoietin-stimulating agents (ESAs), alone or in combination with granulocyte-stimulating factor, are efficacious in patients with low-risk myelodysplastic syndrome (MDS). Moreover, the relative safety of prolonged use of ESA has resulted in widespread use in patients with MDS. We here report a unique case of presacral mass due to extramedullary hematopoiesis (EMH), which was first observed before treatment with ESAs, but which more than doubled in a diameter after 3 years ESA treatment for myelodysplasia. …
Literature
1.
Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, et al. Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes. J Clin Oncol. 2013 31(11):e189–91.CrossRef
Metadata
Title
Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia
Authors
Tatsuya Konishi
Noriko Doki
Yasunobu Takaki
Aiko Igarashi
Kazuteru Ohashi
Publication date
01-01-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2554-8

Other articles of this Issue 1/2019

International Journal of Hematology 1/2019 Go to the issue

Original Article

Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study

Original Article

Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults

Original Article

Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone

Progress in Hematology

Molecular pathogenesis of leukemia and leukemic stem cells (LSCs)

Original Article

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

Progress in Hematology

What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits